ShenGY
2021-11-30
Sad
Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌逾4%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609045413,"tweetId":"609045413","gmtCreate":1638228090236,"gmtModify":1638228090354,"author":{"id":4099261143755430,"idStr":"4099261143755430","authorId":4099261143755430,"authorIdStr":"4099261143755430","name":"ShenGY","avatar":"https://static.tigerbbs.com/e3a5b601d7373e94cf8257ec4aec4f52","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Sad</p></body></html>","htmlText":"<html><head></head><body><p>Sad</p></body></html>","text":"Sad","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609045413","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohu8.com/m/news/1137393357?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌逾4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.</p><p><blockquote>花旗研究部将默克股票评级从买入下调至中性，早盘交易中下跌超过4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物令人失望的业绩限制了默克股票的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁·鲍姆(Andrew Baum)将默克公司的评级从买入下调至中性，他在周一给客户的一份报告中表示，该公司艾滋病毒药物islatravir的开发困难正在削弱默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对MRK的长期投资论点是基于对MRK产品线的低估，尤其是用于艾滋病毒的islatravir，以帮助抵消即将推出的Keytruda[排他性丧失]……我们已从模型中删除了40亿美元的风险调整后2030年估计，减少了我们的每股收益预期高达10%，”该报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克的目标价从每股105美元下调至85美元。新目标比该股周五收盘价高出约7%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌逾4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading<blockquote>默克股价早盘下跌逾4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.</p><p><blockquote>花旗研究部将默克股票评级从买入下调至中性，早盘交易中下跌超过4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Disappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.</p><p><blockquote>花旗表示，一些主要药物令人失望的业绩限制了默克股票的上涨空间。</blockquote></p><p> Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p><p><blockquote>分析师安德鲁·鲍姆(Andrew Baum)将默克公司的评级从买入下调至中性，他在周一给客户的一份报告中表示，该公司艾滋病毒药物islatravir的开发困难正在削弱默克公司的长期潜力。</blockquote></p><p> “Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p><p><blockquote>“我们对MRK的长期投资论点是基于对MRK产品线的低估，尤其是用于艾滋病毒的islatravir，以帮助抵消即将推出的Keytruda[排他性丧失]……我们已从模型中删除了40亿美元的风险调整后2030年估计，减少了我们的每股收益预期高达10%，”该报告称。</blockquote></p><p> Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p><p><blockquote>花旗将默克的目标价从每股105美元下调至85美元。新目标比该股周五收盘价高出约7%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":2156,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609045413"}
精彩评论